Cardiovascular risk markers in patients with primary aldosteronism: A systematic review and meta-analysis of literature studies by Ambrosino, Pasquale et al.
International Journal of Cardiology 208 (2016) 46–55
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdCorrespondenceCardiovascular risk markers in patients with primary aldosteronism:
A systematic review and meta-analysis of literature studiesPasquale Ambrosino a,1,2, Roberta Lupoli a,1,2, Anna Tortora a,2,Marianna Cacciapuoti a,2, Gelsy Arianna Lupoli a,2,
Paolo Tarantino a,2, Aurelio Nasto b,2, Matteo Nicola Dario Di Minno c,d,⁎,2
a Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
b Department of Surgery, Unit of General Surgery and Oncology, Andrea Tortora Hospital, Pagani, Italy
c Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Italy
d Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino, IRCCS, Milan, ItalyAbbreviations: PA, Primary Aldosteronism; CV,
hypertension; IMT, Intima-media thickness; FMD, Fl
Nitrate-mediated dilation; PWV, Pulse-wave velocity;
Ankle-brachial index; PRISMA, Preferred Reporting Item
Meta-Analyses; Aortic-PWV, Carotid-femoral PWV; Brac
ba-PWV, Brachial-ankle PWV; AIx@75, AIx normalized
NOS, Newcastle–Ottawa Scale; MD, Mean difference; 95
OR, Odds Ratio; mm, Millimeters; m/s, Meters per secon
mass index; TC, Total cholesterol; LDLc, LDL-cholestero
Triglycerides; SMD, Standardized mean difference.
⁎ Corresponding author at: Department of Advanced B
Cardiology, Federico II University, Via S. Pansini 5, 80131
E-mail address: dario.diminno@hotmail.it (M.N.D. Di M
1 The two Authors equally contributed to this study.
2 This Author takes responsibility for all aspects of the r
of the data presented and their discussed interpretation.
http://dx.doi.org/10.1016/j.ijcard.2016.01.200
0167-5273/© 2016 Elsevier Ireland Ltd. All rights reserveda b s t r a c ta r t i c l e i n f oArticle history:
Received 21 November 2015
Received in revised form 8 January 2016
Accepted 15 January 2016
Available online 21 January 2016Background/objectives: Several studies reported an increased cardiovascular (CV) morbidity and mortality in
patients with primary aldosteronism (PA).We performed ameta-analysis on the impact of PA onmajormarkers
of CV risk.
Methods: Studies on the relationship between PA and common carotid artery intima-media thickness (CCA-IMT),
prevalence of carotid plaques, ﬂow-mediated dilation (FMD), nitrate-mediated dilation (NMD), pulse-wave
velocity (PWV), augmentation index (AIx), and ankle-brachial index (ABI) were systematically searched in the
PubMed, Web of Science, Scopus and EMBASE databases.
Results: 12 case–control studies (445 cases, 472 controls) were included. Compared to subjects with essential
hypertension (EH), PA patients showed a higher CCA-IMT (MD: 0.12 mm; 95% CI: 0.09, 0.16; P b 0.00001),
and a higher aortic-PWV (272 cases and 240 controls, MD: 1.39 m/s; 95% CI: 0.90, 1.87; P b 0.00001). In contrast,
non-signiﬁcant differenceswere found inAIx and AIx normalized to a heart rate of 75 beats perminute (AIx@75).
When compared to normotensive subjects, PA patients showed signiﬁcantly higher CCA-IMT (MD: 0.16mm; 95%
CI: 0.05, 0.27; P = 0.004), aortic-PWV (MD: 3.74 m/s; 95% CI: 3.43, 4.05; P b 0.00001), AIx@75 (MD: 8.59%; 95%
CI: 0.69, 16.50; P = 0.03), and a signiﬁcantly lower FMD (MD: −2.52%; 95% CI: −3.64, −1.40; P b 0.0001).
Sensitivity and subgroup analyses substantially conﬁrmed our results. Metaregression models showed that
male gender, diabetes, and smoking habit impact on the observed results.
Conclusions: PA appears signiﬁcantly associated with markers of subclinical atherosclerosis and CV risk. These
ﬁndings could help establish more speciﬁc CV prevention strategies in this clinical setting.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
Primary aldosteronism
Subclinical atherosclerosis
Intima-media thickness
Pulse-wave velocity
Arterial stiffness
Flow-mediated dilationCardiovascular; EH, Essential
ow-mediated dilation; NMD,
AIx, Augmentation index; ABI,
s for Systematic reviews and
hial-PWV, Carotid-radial PWV;
to a 75 beats/min heart rate;
% CI, 95% Conﬁdence Interval;
d; cm, Centimeters; BMI, Body-
l; HDLc, HDL-cholesterol; TGs,
iomedical Sciences, Division of
Naples, Italy.
inno).
eliability and freedom from bias
.1. Introduction
PA is the most frequent endocrine cause of secondary hypertension
that affects 5–13% of hypertensive patients [1] and up to 20% of subjects
with resistant hypertension [2]. It is charachterized by autonomous
aldosterone overproduction, which is caused in most cases by adreno-
cortical adenoma or bylateral adrenal hyperplasia [3]. This results in
potassium excretion, sodium reabsorption and ﬂuid retention, thus
leading to increased systolic and diastolic blood pressure [4].
In addition to these well known effects, it has been reported that
patients with PA experience more CV events [3], with increased inci-
dence of myocardial infarction and stroke, and increased prevalence
of atrial ﬁbrillation [5]. Moreover, both retrospective and prospective
studies suggest that individuals with PA might be at a higher risk of
CV mortality than patients with EH [6,7].
However, such an increased CV morbidity and mortality cannot
be entirely explained by the increased blood pressure [8] and the
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gested that the prolonged exposure to high aldosterone concentrations
may result in renal and metabolic sequelae [9], with endothelial dys-
function andmyocardial and/or vascular remodeling [10,11]. To further
address this issue, a growing attention has been given to the assessment
of the association between PA and subclinical atherosclerosis, a recog-
nized marker of CV disease [12].
Carotid IMT assessment is a non-invasive imaging test for subclinical
atherosclerosis [13,14], and it has been widely accepted as one of the
strongest predictors of major CV events (stroke, myocardial infarction,
or CV death) [15,16]. Similarly, FMD, NMD, PWV, AIx, and ABI are
considered surrogate markers of subclinical atherosclerosis and inde-
pendent predictors of CV events [17–20]. FMD and NMD are widely
accepted as accurate and non-invasive methods to assess endothelial
function in humans [21], while PWV and AIx aremeasures of peripheral
and central arterial stiffness [22]. Thus, these CV risk markers provide
important prognostic data over and above traditional CV risk factors.
During recent years, a series of case–control studies reported accel-
erated atherosclerosis [23,24] impaired endothelial function [25,26],
and increased arterial stiffness [27,28] in patients with PA. However,
the evidence is limited by small sample size and potential confounding
factors and no meta-analytical data providing an overall information
about this issue are currently available.
In order to provide a comprehensive overview of the relationship
between PA and subclinical atherosclerosis, we performed a systematic
reviewwithmeta-analysis of literature studies evaluating the impact of
PA on the major markers of CV risk.
2. Methods
A protocol for this review was prospectively developed, detailing
the speciﬁc objectives, the criteria for study selection, the approach to
assess study quality, the outcomes, and the statistical methods.
2.1. Search strategy
To identify all available studies, a detailed search pertaining to PA
and the markers of CV risk (i.e. IMT, FMD, NMD, PWV, AIx, and ABI)
was conducted according to PRISMA guidelines [29]. A systematic
search was performed in the electronic databases (PubMed, Web of
Science, Scopus, EMBASE), using the following search terms in all possi-
ble combinations: primary aldosteronism, hyperaldosteronism, Conn
syndrome, intima-media thickness, carotid plaques, atherosclerosis, ﬂow-
mediated dilation, nitrate-mediated dilation, endothelium-dependent
dilation, endothelium-independent dilation, endothelial dysfunction, pulse
wave velocity, augmentation index, arterial stiffness, ankle-brachial
index. The last search was performed on 30th October 2015. The
search strategy was developed without any language or publication
year restriction.
In addition, the reference lists of all retrieved articles weremanually
reviewed. In case of missing data, study Authors were contacted by
e-mail to try to retrieve original data. Two independent Authors
(PA andMNDDM) analyzed each article and performed the data extrac-
tion independently. In case of disagreement, a third investigator was
consulted (RL). Discrepancies were resolved by consensus. Selection
results showed a high inter-reader agreement (κ = 0.97) and have
been reported according to PRISMA ﬂowchart (Fig. S1).
2.2. Data extraction and quality assessment
According to the pre-speciﬁed protocol, all studies evaluating the
impact of PA on the markers of CV risk were included. Case-reports,
case-series without a control group, reviews and animal studies were
excluded. To be included in the analysis, a study had to provide values
(means with standard deviation) of at least one variable among the
following: common carotid artery IMT (CCA-IMT), brachial arteryFMD or NMD, aortic-PWV, brachial-PWV, ba-PWV, aortic AIx, aortic
AIx@75, and ABI. Studies reporting the prevalence of carotid plaques
were also included.
In each study, data regarding sample size, major clinical and de-
mographic variables, values of CCA-IMT, FMD, NMD, aortic-PWV,
brachial-PWV, ba-PWV, AIx, AIx@75, and ABI, and prevalence of
carotid plaques in PA patients and controls were extracted. Controls
were represented by patients with EH and/or subjects normal blood
pressure.
Given the characteristics of the included studies, the evaluation
of methodological quality of each study was performed with the
Newcastle–Ottawa Scale (NOS), which is speciﬁcally developed to
assess quality of non-randomized observational studies [30]. The scor-
ing systemencompasses threemajor domains (selection, comparability,
exposure) and a resulting score range between 0 and 8, a higher score
representing a better methodological quality. Results of the NOS quality
assessment are reported in Table S1.2.3. Statistical analysis and risk of bias assessment
Statistical analysis was carried out using Review Manager [Version
5.2, The Cochrane Collaboration, Copenhagen, Denmark] provided by
The Cochrane Collaboration.
Differences among cases and controls were expressed as MD with
pertinent 95% CI for continuous variables, and as OR with pertinent
95% CI for dichotomous variables.
CCA-IMT has been expressed in mm, FMD, NMD, AIx, and AIx@75 as
percentage (%), aortic-PWV and brachial-PWV have been expressed in
m/s, ba-PWV in cm/s, and ABI as absolute number.
The overall effect was tested using Z scores and signiﬁcance was set
at P b 0.05. Statistical heterogeneity between studies was assessed with
chi square Cochran's Q test and with I2 statistic, which measures the
inconsistency across study results and describes the proportion of
total variation in study estimates, that is due to heterogeneity rather
than sampling error. In detail, I2 values of 0% indicates no heterogeneity,
25% low, 25–50% moderate, and 50% high heterogeneity [31].
Publication bias was assessed by the Egger's test and represented
graphically by funnel plots of the standard difference in means versus
the standard error. Visual inspection of funnel plot asymmetry was
performed to address for possible small-study effect, and Egger's test
was used to assess publication bias, over and above any subjective eval-
uation. A P b 0.10 was considered statistically signiﬁcant [32]. In case of
a signiﬁcant publication bias, the Duval and Tweedie's trim and ﬁll
methodwith the random-effectmodelwas used to allow for the estima-
tion of an adjusted effect size [33].
In order to be as conservative as possible, the random-effectmethod
was used for all analyses to take into account the variability among
included studies.2.4. Sensitivity analyses
We repeated analyses by including only the studies judged as “high
quality” according to NOS (i.e. NOS ≥ to the median value found among
included studies).
In order to avoid the risk of data overlap, a further sensitivity analysis
was performed after excluding studies enrolling patients in the same
period time from the same recruitment centers as other included
studies.2.5. Subgroup analyses
Given the potential inﬂuence of PA etiology on the outcomes, we
planned to perform separate analyses of studies only including patients
with aldosterone-producing adenoma.
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We hypothesized that differences among included studies may be
affected by demographic variables (mean age, female gender) and
clinical data related to the coexistence of traditional CV risk factors
(smoking habit, diabetes mellitus, obesity, hyperlipidemia). To assess
the possible effect of such variables in explaining different results ob-
served across studies, we planned to performmeta-regression analyses
after implementing a regression model with changes in CCA-IMT, FMD,
NMD, aortic-PWV, brachial-PWV, ba-PWV, AIx, AIx@75, and ABI values,
or presence of carotid plaques as dependent variables (y) and the above
mentioned co-variates as independent variables (x). This analysis
was performed with Comprehensive Meta-analysis [Version 2, Biostat,
Englewood NJ (2005)].3. Results
After excludingduplicate results, the search retrieved 236 articles. Of
these studies, 189 were excluded because they were off the topic after
scanning the title and/or the abstract, 32 because they were reviews/
comments/case reports or they lacked of data of interest. Other 3 studies
were excluded after full-length paper evaluation.
Thus, 12 articles (on 445 PA patients and 472 controls) were includ-
ed in theﬁnal analysis [3,23,24,25,26,27,28,34–38] (Fig. S1). In detail, 10
studies [3,23,24,27,28,34–38] compared 384 PA patients with 333 EH
subjects, of which 4 studies with data on CCA-IMT (5 data-sets on 118
cases and 118 controls), 7 reporting on aortic-PWV (on 272 patients
and 240 controls), 2 on AIx (on 73 cases and 48 controls), and 2 on
AIx@75 (on 50 cases and 61 controls). FMD has been evaluated in 1
study [39], while no study tested NMD, brachial-PWV, ba-PWV, ABI,
and the prevalence of carotid plaques in PA patients and EH subjects.Table 1
Demographic and clinical data of patients with primary aldosteronism (PA), essential hyperten
Author Pop
(n)
M/F Age
(years)
Smoking
(%)
DM
(%)
O
(
Bernini 2008 PA 23 15/8 53.9 13 0 –
EH 24 14/10 50.6 8.3 0 –
NBP 15 10/5 49.9 13.3 0 –
Chang 2015 PA 37 17/20 43.4 – – –
EH 20 8/12 45.0 – – –
Holaj 2007 PA 33 20/13 57.0 33 24 –
EH 52 32/20 55.0 38 21 –
NBP 33 17/16 54.0 24 0 –
Holaj 2015 PA 21 13/8 51.4 24 24 –
PA 21 11/10 51.3 38 33 –
EH 21 13/8 55.6 29 19 –
Lin 2012 PA 20 11/9 46.0 – – –
EH 21 8/13 48.0 – – –
Mark 2014 PA 14 11/3 58.4 – 7.1 –
EH 33 28/5 54.8 – 6.1 –
NBP 17 10/7 51.8 – 0 –
Nishizaka 2004
PA 36 29/7 50.0 0 0 –
NBP 44 24/20 55.0 0 0 –
Rosa 2012⁎ PA 49 36/13 51.0 45 – –
EH 49 33/16 50.0 31 – –
Strauch 2006 PA 36 – 52.0 – – –
EH 28 – 49.0 – – –
NBP 20 – 46.0 – – –
Tsiouﬁs 2008 PA 17 10/7 55.0 31 0 –
EH 30 17/13 58.0 33 0 –
Tsuchiya 2009 PA 25 14/11 57.3 – – –
NBP 10 5/5 63.6 – – –
Wu 2011 PA 113 47/66 49.6 18.6 11.5 –
EH 55 20/35 50.2 10.9 7.3 –
PA: primary aldosteronism; EH: essential hypertension; Pop: population; M/F: male/female; H
index; TC: Total Cholesterol; LDLc: LDL-cholesterol; HDLc: HDL-cholesterol; TGs: triglycerides;
otherwise indicated.
⁎ TG values are expressed as median.In addition, 6 studies [23–27,36] compared 167 PA patients with
139 normotensive subjects, of which 3 studies with data on CCA-IMT
(on 81 cases and 58 controls), 2 reporting on FMD (on 61 patients and
54 controls), 3 on aortic-PWV (on 73 cases and 52 controls), and 2 on
AIx@75 (on 73 cases and 58 controls). NMD, ba-PWV, and AIx were
evaluated in 1 study each [26,36]. Moreover, no study tested brachial-
PWV, ABI, and the prevalence of carotid plaques in PA patients and nor-
motensive subjects.
3.1. Study characteristics
All included studies had a case–control design. Major characteristics
of populations are shown in Table 1.
The number of patients varied from 14 to 113, the mean age from
43.4 to 58.4 years, and the prevalence of male gender from 41.6% to
78.6%.
The presence of diabetes mellitus was reported by 0%–33% of
patients, smoking habit by 0%–45%, and hyperlipidemia by 34.5%–34.8%.
MeanBMI varied from22.4 kg/m2 to 33.6 kg/m2 but no study report-
ed on the prevalence of obese subjects. Mean values of TC ranged from
4.83 to 5.04mmol/l, of LDLc from2.10 to 3.31mmol/l, of HDLc from1.20
to 1.55 mmol/l, and of TGs from 1.21 to 1.61 mmol/l.
The NOS for quality assessment of included studies showed a
median value of 6.
3.2. Primary aldosteronism versus essential hypertension
In 4 studies (5 data-sets) [23–25,35], we found a signiﬁcantly higher
CCA-IMT in 118 PA patients than in 118 EH subjects (MD: 0.12mm; 95%
CI: 0.09, 0.16; P b 0.00001, Fig. 1A), without signiﬁcant heterogeneity
among studies (I2 = 37%; P = 0.18).sion (EH) and normal blood pressure (NBP) in included studies.
b
%)
HL
(%)
BMI
(kg/m2)
TC
(mmol/l)
LDLc
(mmol/l)
HDLc
(mmol/l)
TGs
(mmol/l)
34.8 29.0 4.98 3.08 1.20 1.35
25 26.9 5.36 3.20 1.50 1.44
0 25.8 5.07 3.10 1.34 1.38
– – – – – –
– – – – – –
– 29.0 4.98 2.99 1.30 1.54
– 28.4 5.28 3.06 1.38 1.85
– 26.6 5.59 3.19 1.61 1.73
– 29.2 4.83 2.81 1.28 1.63
– 29.8 4.95 2.99 1.34 1.63
– 29.2 5.21 3.21 1.25 1.67
– – – – – –
– – – – – –
– 29.8 – 2.10 – –
– 29.1 – 2.90 – –
– 25.8 – – – –
– 33.6 – – – –
– 34.5 – – – –
– 29.7 4.9 3.0 1.20 1.30
– 30.1 4.8 2.9 1.20 1.40
– 27.7 4.90 2.80 1.40 –
– 28.1 5.10 2.90 1.40 –
– 25.3 5.30 3.10 1.68 –
– 30.3 – 3.31 1.29 1.43
– 28.3 – 3.36 1.34 1.31
– 22.4 – 2.76 1.55 1.21
– 21.2 – 3.13 1.47 1.30
34.5 24.9 5.04 – 1.21 1.61
34.5 24.3 5.04 – 1.24 1.47
T: hypertension; DM: diabetes mellitus; Ob: obesity; HL: hyperlipidemia; BMI: body mass
NA: not assessed. Age, BMI, TC, LDLc, HDLc, and TGs are expressed as mean values, unless
Fig. 1. Cardiovascular risk markers in patients with primary aldosteronism (PA) and in controls with essential hypertension (EH). Panel A: common carotid artery intima-media thickness
(CCA-IMT). Panel B: carotid-femoral pulse-wave velocity (aortic-PWV). Panel C: augmentation index (AIx). Panel D: augmentation index normalized to a heart rate of 75 beats perminute
(AIx@75).
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240 controls, showed that PA patients have a signiﬁcantly higher
aortic-PWV as compared to EH subjects (MD: 1.39 m/s; 95% CI: 0.90,
1.87; P b 0.00001, Fig. 1B). The heterogeneity among studies was signif-
icant (I2 = 71%; P = 0.002) and it was not reduced after excluding
1 study at time.
In contrast, no signiﬁcant association between PA and an increased
AIx was found in 2 studies [3,36] on 73 cases and 48 controls (MD:5.12%; 95% CI:−3.94, 14.17; P= 0.27, Fig. 1C). Similarly, no differences
in AIx@75 were reported among 50 PA and 61 EH subjects [27,36]
(MD:−0.54%; 95% CI:−3.78, 2.70; P = 0.74, Fig. 1D).
3.3. Primary aldosteronism versus normal blood pressure
Three studies [23,24,26] on a total of 81 cases and 58 controls,
showed a signiﬁcantly higher CCA-IMT in patients with PA than in
50 P. Ambrosino et al. / International Journal of Cardiology 208 (2016) 46–55normotensive controls (MD: 0.16 mm; 95% CI: 0.05, 0.27; P =
0.004, Fig. 2A). Signiﬁcant heterogeneity among studies was found
(I2 = 90%; P b 0.00001), not reduced by the one-study-at-time
exclusion.
A signiﬁcantly lower FMD was found in 2 studies [25,26] on
61 cases and 54 controls (MD: −2.52%; 95% CI: −3.64, −1.40;
P b 0.0001, Fig. 2B), without signiﬁcant heterogeneity (I2 = 52%;
P = 0.15).
In addition, a total of 3 studies [23,27,36] (73 cases and 52 controls)
showed that PA patients have a signiﬁcantly higher aortic-PWV as com-
pared to subjects with normal blood pressure (MD: 3.74 m/s; 95% CI:
3.43, 4.05; P b 0.00001, Fig. 2C), with no heterogeneity among studies
(I2 = 0%; P = 0.89).
Furthermore, 2 studies [27,36] showed signiﬁcantly higher AIx@75
in 50 PA patients than 37 normotensive subjects (MD: 8.59%; 95% CI:
0.69, 16.50; P = 0.03, I2 = 72%; P = 0.06, Fig. 2D).Fig. 2.Cardiovascular riskmarkers in patientswith primary aldosteronism (PA) and in normoten
ﬂow-mediated dilation (FMD). Panel C: carotid-femoral pulse-wave velocity (aortic-PWV). Pan3.4. Publication bias
Because it is recognized that publication bias can affect the results of
meta-analyses, we attempted to assess this potential bias using funnel
plots analysis.
Visual inspection of funnel plots for studies on PA patients and EH
subjects suggested the absence of publication bias and of small-study ef-
fect for aortic-PWV (Fig. S2), conﬁrmedby the Egger's test (P=0.64). In
contrast, an asymmetric distribution of studies around the mean was
found for studies evaluating CCA-IMT (Fig. S2), and the Egger's test con-
ﬁrmed a signiﬁcant publication bias (P = 0.008). Interestingly, the ad-
justed effect size, estimated by the Duval and Tweedie's trim and ﬁll
method, substantially conﬁrmed results for CCA-IMT (MD: 0.14 mm;
95% CI: 0.11, 0.17).
When considering the studies on PA patients and normotensive sub-
jects, the distribution was rather symmetrical for CCA-IMT (Fig. S3) andsive controls. Panel A: common carotid artery intima-media thickness (CCA-IMT). Panel B:
el D: augmentation index normalized to a heart rate of 75 beats per minute (AIx@75).
Table 3
Sensitivity analyses after exclusion of studies potentially reporting on the samepopulation
as other included studies.
N of studies N of patients Effect size
MD [95% CI]
Primary aldosteronism versus essential hypertension
CCA-IMT 3
(4 data-sets)
85 patients
77 controls
MD: 0.13 mm [0.09, 0.16]; P b 0.00001
I2 = 31%; P = 0.23
Aortic-PWV 5 216 patients
191 controls
MD: 1.29 m/s [0.69, 1.89]; P b 0.0001
I2 = 75%; P = 0.003
AIx 2 73 patients
48 controls
MD: 5.12% [−3.94, 14.17]; P = 0.27
I2 = 66%; P = 0.09
AIx@75 2 50 patients
61 controls
MD:−0.54% [−3.78, 2.70]; P = 0.74
I2 = 0; P = 0.57
Primary aldosteronism versus normal blood pressure
CCA-IMT 3 81 patients
58 controls
MD: 0.16 mm [0.05, 0.27]; P = 0.004
I2 = 90%; P b 0.0001
FMD 2 61 patients
54 controls
MD:−2.52% [−3.64,−1.40]; P b 0.0001
I2 = 52; P = 0.15
Aortic-PWV 3 73 patients
52 controls
MD: 3.74 m/s [3.43, 4.05]; P b 0.000001
I2 = 0%; P = 0.89
AIx@75 2 50 patients
37 controls
MD: 8.59% [0.69, 16.50]; P = 0.03
I2 = 72%; P = 0.06
N: number; MD: mean difference; 95% CI: 95% Conﬁdence Intervals; CCA-IMT: common
carotid artery intima-media thickness; aortic-PWV: carotid-femoral pulse-wave velocity;
AIx: augmentation index; AIx@75: augmentation index normalized to a 75 beats/min
heart rate; FMD: ﬂow-mediated dilation; NA: not applicable.
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visual inspection of funnel plots of effect size versus standard error for
studies evaluating aortic-PWV showed an asymmetric distribution of
studies around the mean (Fig. S3), with signiﬁcant publication bias
(Egger's test P = 0.03). However, the adjusted effect size, estimated
by the Duval and Tweedie's trim and ﬁll method, conﬁrmed our results
on aortic-PWV (MD: 3.70 m/s; 95% CI: 3.39, 4.00).
The small sample-size and the low number of studies made publica-
tion bias assessment unlikely to be performed for all the other evaluated
outcomes.
3.5. Sensitivity analyses
The median value of NOS quality assessment was 6. Thus, the
analyses were repeated by including only the 8 studies classiﬁed as
“high quality” (NOS ≥6) [3,23–25,28,34,37,38] (Table S1). Of interest,
after excluding studies classiﬁed as “low quality” [26,27,35,36], our
results were substantially conﬁrmed (Table 2).
Similar results were conﬁrmed also after excluding studies [24,35,
36] potentially reporting on the same population as other included
studies [28,34,38] (Table 3).
3.6. Subgroup analysis
Given the potential inﬂuence of PA etiology on the evaluated out-
comes, we planned to perform separate analyses of studies speciﬁcally
enrolling patients with aldosterone-producing adenoma. However,
considering the low number of studies (n = 3) [3,34,35], a subgroup
analysis could be performed only for CCA-IMT. In particular, compared
to EH subjects, a signiﬁcantly higher CCA-IMT was conﬁrmed in PA
patients with adrenocortical adenoma (MD: 0.10 mm; 95% CI: 0.05,
0.15), without heterogeneity among studies (I2 = 0%; P = 0.77).
3.7. Meta-regression analyses
Regression models for studies comparing PA patients and EH
subjects showed that the presence of diabetes and smoking habit signif-
icantly impacted on CCA-IMT. In particular, increasing percentages
of diabetics and smokers were associated with a lower difference in
CCA-IMT between PA patients and EH controls (Z =−2.31; P = 0.02,
Fig. 3A, and Z =−2.28; P = 0.02, Fig. 3B, respectively).Table 2
Sensitivity analyses on “high quality” studies (i.e. Newcastle–Ottawa Scale ≥6).
N of studies N of patients Effect size
MD [95% CI]
Primary aldosteronism versus essential hypertension
CCA-IMT 3
(4 data-sets)
98 patients
97 controls
MD: 0.12 mm [0.08, 0.16]; P b 0.00001
I2 = 46%; P = 0.14
Aortic-PWV 5 216 patients
191 controls
MD: 1.29 m/s [0.69, 1.89]; P b 0.0001
I2 = 75%; P = 0.003
AIx 1 37 patients
20 controls
MD: 10.30% [1.61, 18.99]; P = 0.02
I2 = NA; P = NA
AIx@75 1 14 patients
33 controls
MD:−1.10% [−4.88, 2.68]; P = 0.57
I2 = NA; P = NA
Primary aldosteronism versus normal blood pressure
CCA-IMT 2 56 patients
48 controls
MD: 0.22 mm [0.15, 0.29]; P b 0.00001
I2 = 78%; P = 0.003
FMD 1 36 patients
44 controls
MD:−2.10% [−2.80,−1.40]; P b 0.00001
I2 = NA; P = NA
Aortic-PWV 2 37 patients
32 controls
MD: 3.71 m/s [3.38, 4.35]; P b 0.000001
I2 = 0%; P = 0.76
AIx@75 1 14 patients
17 controls
MD: 4.90% [−0.01, 9.81]; P = 0.05
I2 = NA; P = NA
N: number; MD: mean difference; 95% CI: 95% Conﬁdence Intervals; CCA-IMT: common
carotid artery intima-media thickness; aortic-PWV: carotid-femoral pulse-wave velocity;
AIx: augmentation index; AIx@75: augmentation index normalized to a 75 beats/min
heart rate; FMD: ﬂow-mediated dilation; NA: not applicable.Similarly, an increasing percentage of patients with smoking habit
was also associated with a low effect size for aortic-PWV (Z =−3.78;
P b 0.001, Fig. 4).
When analyzing regression models for studies on PA patients and
normotensive subjects, male gender signiﬁcantly impacted on CCA-
IMT. An increasing percentage of males was associated with a higher
difference in CCA-IMT between PA patients and normotensive controls
(Z = 2.83; P = 0.005, Fig. 5).
All the other demographic and clinical data did not impact on the
evaluated outcomes.
4. Discussion
Results of the present meta-analysis consistently show that PA is
associated with subclinical atherosclerosis and increased arterial stiff-
ness. In particular, compared to both hypertensive and normotensive
subjects, we reported an increased CCA-IMT and aortic-PWV in patients
with PA. In addition, when compared to controls with normal blood
pressure, PA patients also showed increased AIx and AIx@75 and
impaired endothelial function (as expressed by a reduced FMD). Our
ﬁndings are strengthened by the sensitivity and subgroup analyses.
Moreover, regression models were able to further reﬁne results provid-
ing the evidence that male gender, diabetes, and smoking habit may
signiﬁcantly impact on the evaluated outcomes.
Overall, these data clearly show an increased CV risk in patients with
PA and suggest the need for a strict monitoring of CV risk factors and of
early signs of subclinical atherosclerosis in this clinical setting. Accord-
ingly, previous published studies reported an increased risk of major
CV events [3] and CV death in PA patients when compared to EH
subjects [6]. The German Conn's Registry recently reported that CVmor-
tality is the main cause of death in PA (50% versus 34% in EH) [7].
Many CV risk factors are thought to have a causal role in the athero-
sclerotic process [40]. Although PA patients are hypertensive subjects,
the relationship between subclinical atherosclerosis and PA seems to
be more complex and the presence of hypertension might not entirely
explain the accelerated atherosclerotic process in this clinical setting
[8]. Thus, other mechanisms have been proposed to explain the rela-
tionship between PA and atherosclerosis.
Growing evidence suggests that it is the long-term exposure to high
aldosterone levels to determine a deleterious effect on the CV system by
Fig. 3.Meta-regression analyses: impact of demographic and clinical variables on effect size assessed with regression-based techniques. Primary aldosteronism (PA) versus
essential hypertension (EH): effects of diabetes (Panel A) and smoking habit (Panel B) on common carotid artery intima-media thickness (CCA-IMT). The area of each circle
is proportional to the study weight in the meta-regression. Increasing percentages of diabetics and smokers are associated with a lower difference in CCA-IMT between PA
patients and EH controls.
Fig. 4.Meta-regression analyses: impact of demographic and clinical variables on effect size assessed with regression-based techniques. Primary aldosteronism (PA) versus essential
hypertension (EH): effect of smoking habit on carotid-femoral pulse wave velocity (aortic-PWV). The area of each circle is proportional to the study weight in the meta-regression. An
increasing percentage of smokers is associated with a lower difference in aortic-PWV between PA patients and EH controls.
Fig. 5.Meta-regression analyses: impact of demographic and clinical variables on effect size assessed with regression-based techniques. Primary aldosteronism (PA) versus normal blood
pressure: effect ofmale gender on CCA-IMT. The area of each circle is proportional to the studyweight in themeta-regression. An increasing percentage ofmales is associatedwith a higher
difference in CCA-IMT between PA patients and normotensive controls.
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effects [41–43]. Aldosterone excess contributes to ﬁbrosis and thicken-
ing of the arterial wall [24], and adversely affect endothelial function
by enhancing oxidative stress and inﬂammation [44,45]. It has been
suggested that aldosterone is able to induce vascular smooth muscle
cell hypertrophy or hyperplasia with adventitial cell migration [46].
Moreover, aldosterone excess has been associated with hypertrophy
of cardiac myocytes [47]. These alodosterone-induced changes result
in vascular remodeling,46 accompanied by increased left ventricular
mass47 and increased IMT [48]. Aldosterone also induces changes in
the extracellular matrix, leading to collagen deposition [49], and subse-
quently, to arterial stiffening [36] and myocardial ﬁbrosis [41,50]. The
role of aldosterone in the changes of vascular collagen accumulation is
further conﬁrmed by the evidence that the aldosterone antagonist
spironolactone has been able to prevent the development of aortic
ﬁbrosis in animal models [51].
Overall, our ﬁndings are in line with all available experimental and
clinical evidences, supporting the hypothesis that premature athero-
sclerosismaybe one of themain features of PA and that vascular remod-
eling induced by long-term exposure to high aldosterone levels plays an
important pathogenic role. Thus, aldosterone excess may act indepen-
dently and/or synergistically with hypertension and traditional CV risk
factors.
In order to provide a comprehensive overview of the relationship
between PA and subclinical atherosclerosis, all the major recognized
markers of CV risk were taken into account in the current meta-
analysis. Moreover, with the aim to exclude the potential interference
of PA-related hypertension on our results, we tried to compare PA
patients to both hypertensive and normotensive subjects. As a matter
of fact, our results on CCA-IMT and aortic-PWV were substantially con-
ﬁrmed both in comparison to EH and to normal blood pressure subjects,
thus conﬁrming an independent role of aldosterone excess on CV risk. In
addition, we performed meta-regression analyses to evaluate whether
clinical and demographic variables may impact on the observed results.
As expected, regression models showed that results are conditioned by
an increasing prevalence of traditional CV risk factors (i.e. smoking habit
and diabetes mellitus) that was associated with a lower effect size. In
addition, compared to normotensive subjects, PA patients also showed
impaired FMD and increased AIx and AIx@75. The latter results on
arterial stiffness parameters (AIx and AIx@75) could not be conﬁrmed
in the analyses versus EH. However, when interpreting this result, we
should also consider the limited number of studies (n = 2) evaluating
this outcomes. In keepingwith this, the low number of available studies
on the other searched markers of CV risk (i.e. NMD, brachial-PWV, ba-
PWV, ABI) made any further meta-analytical evaluation unlikely to be
performed.
The clinical relevance of these results and the need for a strict
monitoring of subclinical signs of atherosclerosis in PA patients can be
better understood if we consider that the risk of myocardial infarction
increases of 43% every 0.163 mm increase in carotid IMT [52,53] while
the risk of major CV events rises of about 14% each 1 m/s increase in
aortic-PWV [19]. In addition, it is important to highlight that growing
attention has been given to PA in the last years because recent data
consistently suggest that its prevalence is not negligible, acoounting
for 5–13% of hypertensive patients of any causes [54].
Our results support the need for large long-term interventional trials
with CV end-points to investigate whether disease remission obtained
with appropriate surgical and/or medical treatments may modify the
CV risk in PA patients.
5. Limitations
Some potential limitations of our study need to be discussed. First,
studies included in our meta-analysis have different inclusion and
exclusion criteria and most of patients included in the analysis had
concomitant CV risk factors (smoking, obesity, diabetes mellitus,hyperlipidemia). Since meta-analysis is performed on aggregate data
and somemissing information is present in each study, themultivariate
approach allowed for the adjustment for some (but not all) potential
confounders. Thus, although results of meta-regression analyses were
able to reﬁne analyses by assessing the inﬂuence of most clinical and
demographic variables on the observed results, caution is necessary in
overall results interpretation.
Second, heterogeneity among the studies was generally signiﬁcant.
Althought it was not possible to conclusively ascertain sources of het-
erogeneity, all results were conﬁrmed after adjustment for potential
publication bias.
Another potential limitation is the presence of other clinical condi-
tions potentially impacting on aldosterone levels (i.e. chronic kidney
disease, atrial ﬁbrillation) [55,56]. None of included studies reported
the number of patients with any of these diseases. Thus, it was not
possible to assess the impact on our outcomes. However, the present
meta-analysis has been speciﬁcally designed to evaluate patients with
PA, which is caused in most cases by adrenocortical adenoma or
bylateral adrenal hyperplasia. Thus, we are conﬁdent that the impact
of potential confounding factors may be marginal.
Moreover, at variencewith IMT,measurement of PWV, AIx, and FMD
may be inﬂuenced by many confounding factors, signiﬁcantly limiting
reproducibility of arterial stiffness and endothelial dysfunction assess-
ment [57,58,59] and, in turn, the relevance of our results. Moreover,
we have to consider that differences among assessment techniques
and devices, as well as the lack of comparable age-adjusted normal
values may limit the validity of these parameters as markers of early
atherosclerosis. Thus, caution is necessary in overall results interpreta-
tion. However, in the attempt to overcome this potential limitation,
we repeated the analyses by using SMD instead of MD, being this
method designed to be used when different methods of measurement
are analyzed togheter [31]. Interestingly, all results were conﬁrmed
with using SMD (data not shown).
6. Conclusion
PA is signiﬁcantly associated with subclinical atherosclerosis and, in
turn,with an increased CV risk. Thus, patients with PAmay beneﬁt from
a periodic assessment of surrogate markers of CV risk and this could
help establish more speciﬁc CV prevention strategies for these patients.
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